Adam Berger, MD
Ophthalmology · Winter Haven, FLNPI 1972574408
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Onmark, Inc. accounts for 60.6% of it on its own, with 16 other manufacturers making up the rest. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $133.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Onmark, Inc.$10K
- US Oncology Corporate, Inc.$2K
- Kyowa Kirin, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$815
- Genentech USA, Inc.$523
- Astellas Pharma US Inc$483
- plus $1K from 11 others
Across 355 payments — averaging $3281.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$574K
- Amgen$153K
- Bayer$140K
- Novartis$102K
- Kyowa Kirin, Inc.$93K
- Mylan Technologies Inc.$45K
- plus $58K from 4 others
What the payments were for
- Consulting fees$7,98048%
- Travel & lodging$3,59822%
- Food & beverage$4,94230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Onmark, Inc. | 14 | $10,016 |
| US Oncology Corporate, Inc. | 4 | $1,861 |
| Kyowa Kirin, Inc. | 7 | $1,420 |
| Regeneron Healthcare Solutions, Inc. | 33 | $815 |
| Genentech USA, Inc. | 20 | $523 |
| Astellas Pharma US Inc | 15 | $483 |
| Alcon Research LLC | 1 | $354 |
| AbbVie(2 entities) | 14 | $286 |
| Bausch & Lomb Americas Inc. | 3 | $199 |
| Novartis | 4 | $186 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $107 |
| Sandoz | 3 | $98 |
| Regeneron | 1 | $53 |
| Dutch Ophthalmic, USA | 1 | $38 |
| Coherus Oncology, Inc. | 1 | $35 |
| Biogen | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIPERE$160
- Izervay$157
- BUPARLISIB$122
How this compares
$16,520 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 130 | $280,024 |
| IzervayAvacincaptad Pegol Sodium/Pf | 43 | $157,230 |
| SyfovrePegcetacoplan/Pf | 33 | $118,435 |
| VabysmoFaricimab-Svoa | 22 | $48,925 |
| CimerliRanibizumab-Eqrn | 11 | $16,591 |
| Prednisolone Acetate | 291 | $10,526 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 102 | $1,512 |
| Gentamicin Sulfate | 95 | $971 |
| Ketorolac Tromethamine | 52 | $764 |
| Latanoprost | 57 | $412 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 27 | $394 |
| Atropine Sulfate | 12 | $358 |
| Dorzolamide Hcl | 14 | $290 |
| Brimonidine Tartrate | 38 | $265 |
| Timolol Maleate | 18 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $815 | $280,024130 claims |
| Astellas Pharma US IncIzervay | $483 | $157,23043 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $23 | $118,43533 claims |
| Genentech USA, Inc.Vabysmo | $523 | $48,92522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Winter Haven
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.